Artemis Medicare Services Ltd
P&L
Quarterly Consolidated
vs Q2 FY25
Artemis Medicare Services Ltd Reports Q3 and 9M FY25 Results: Revenue Up 6.3%, EBITDA Up 34.4%, PAT Up 78.3% Y-o-Y
05 Feb 2025 · 5 Feb 2025, 09:22 pm
Summary
Artemis Medicare Services Ltd, a leading healthcare provider in Delhi NCR, reported its Q3 and 9M FY25 results. The company recorded a consolidated gross revenue of INR 2,431 Mn, up 6.3% Y-o-Y. The EBITDA stood at INR 463 Mn, a significant increase of 34.4% Y-o-Y. The company's PAT was INR 206 Mn, a robust growth of 78.3% Y-o-Y. The average gross revenue per occupied bed (ARPOB) was INR 80,200. The company also reported a bed capacity utilization of 60.4% and a 30% contribution from overseas patients to the net revenue.
Key Highlights
- 1
Q3 FY25 Consolidated Gross Revenue of INR 2,431 Mn; up 6.3% Y-o-Y
- 2
Q3 FY25 EBITDA of INR 463 Mn; up 34.4% Y-o-Y
- 3
Q3 FY25 PAT of INR 206 Mn; up 78.3% Y-o-Y
- 4
Average gross revenue per occupied bed (ARPOB) of INR 80,200
- 5
Overseas patients contributed 30% to Net Revenue
Management Comments
Dr. Devlina Chakravarty
Managing Director of Artemis Medicare Services Ltd
The company has delivered a robust performance in Q3 FY25 and 9M FY25, driven by our unwavering focus on improving key business metrics and operational efficiencies. Despite this being a seasonally muted quarter, we have been able to achieve YoY growth and posted highest ever ARPOB by optimising the payer mix. Additionally, our increasing revenue contribution from international patients underscores our prominence as a preferred destination for Medical Value Travel. To cater to our growing customer base, we are focusing on ramping up the occupancy in the third tower. With this, we expect to further improve our performance by leveraging economies of scale and improving cost efficiencies. During the quarter, we have taken initiatives to enhance operational efficiencies by removing bottlenecks in the processes and improving patient experience. We have also announced advanced tech-driven physiotherapy services in a strategic tie-up with Abhinav Bindra Targeting Performance (ABTP), aiming to revolutionise patient care by offering tailor made services. Aligned with our strategic growth initiatives, we are streamlining our efforts to launch operations at our recently announced Raipur facility within the next year, marking our access into central India. Furthermore, we continue to explore expansion opportunities in the super-speciality segment, allowing us to strengthen our brand, expand our footprint, and achieve our growth plans.
Informational and educational content only. Not investment advice.